We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 19, 2019

Adjuvant Chemotherapy ± Trastuzumab in High-Risk Invasive HER2-Negative Breast Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2
J. Clin. Oncol 2019 Dec 10;[EPub Ahead of Print], L Fehrenbacher, RS Cecchini, CE Geyer, P Rastogi, JP Costantino, JN Atkins, JP Crown, J Polikoff, JF Boileau, L Provencher, C Stokoe, TD Moore, A Robidoux, PJ Flynn, VF Borges, KS Albain, SM Swain, S Paik, EP Mamounas, N Wolmark

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading